Brokerages Set Natus Medical Inc (BABY) Target Price at $44.00

Shares of Natus Medical Inc (NASDAQ:BABY) have been assigned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $44.00.

Several brokerages recently commented on BABY. ValuEngine raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. BidaskClub raised shares of Natus Medical from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Finally, Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Friday, August 10th.

Shares of NASDAQ:BABY opened at $32.01 on Wednesday. The company has a market capitalization of $1.19 billion, a P/E ratio of 22.08 and a beta of 0.59. The company has a quick ratio of 2.19, a current ratio of 2.99 and a debt-to-equity ratio of 0.29. Natus Medical has a one year low of $28.00 and a one year high of $43.60.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, July 25th. The medical equipment provider reported $0.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.09. The business had revenue of $130.70 million during the quarter, compared to the consensus estimate of $130.60 million. Natus Medical had a negative net margin of 4.16% and a positive return on equity of 11.18%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 EPS. On average, research analysts forecast that Natus Medical will post 1.55 earnings per share for the current fiscal year.

In other news, Director Robert A. Gunst sold 12,840 shares of the firm’s stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of $34.66, for a total transaction of $445,034.40. Following the completion of the transaction, the director now owns 54,982 shares of the company’s stock, valued at $1,905,676.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert A. Gunst sold 9,100 shares of the firm’s stock in a transaction on Friday, July 27th. The shares were sold at an average price of $34.11, for a total transaction of $310,401.00. Following the transaction, the director now directly owns 54,982 shares of the company’s stock, valued at approximately $1,875,436.02. The disclosure for this sale can be found here. In the last three months, insiders sold 77,540 shares of company stock valued at $2,804,615. 5.50% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Natus Medical during the first quarter valued at $124,000. US Bancorp DE raised its stake in shares of Natus Medical by 81.2% during the first quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 2,125 shares during the last quarter. Sei Investments Co. raised its stake in shares of Natus Medical by 46.3% during the second quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock valued at $161,000 after acquiring an additional 1,478 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Natus Medical by 1,010.8% during the second quarter. Tower Research Capital LLC TRC now owns 5,132 shares of the medical equipment provider’s stock valued at $177,000 after acquiring an additional 4,670 shares during the last quarter. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Natus Medical during the second quarter valued at $201,000. 96.88% of the stock is owned by hedge funds and other institutional investors.

Natus Medical Company Profile

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Further Reading: Earnings Per Share (EPS)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply